ClinicalTrials.Veeva

Menu

The COMPLETE Study

C

CoreAalst

Status

Enrolling

Conditions

Coronary Artery Disease

Study type

Observational

Funder types

Industry

Identifiers

Details and patient eligibility

About

The COMPLETE study is a single-centre, investigator-initiated study of patients with an indication for invasive coronary angiography with CCTA performed during the diagnostic evaluation. After identifying the presence of a coronary stenosis, defined as an epicardial lesion >50% stenosis on CCTA, patients eligible for the study will be invited to participate.

The main aim of this trial is to assess the accuracy of coronary CT angiography to quantify total atheroma volume with intravascular ultrasound as reference.

Patients will be divided into 2 sub-groups:

Cohort 1: Patients with stable coronary artery disease or stabilized acute coronary syndromes with a clinical indication for invasive coronary angiography.

Cohort 2: Patients previously revascularized with a metallic stent with a clinical indication for invasive coronary angiography.

In both cohorts, patients should have undergone coronary CT angiography as part of the standard of care.

Patients included in the study will be managed according to the standard of care for the assessment of coronary artery disease. Clinical follow-up will be collected until 3 years follow-up.

Enrollment

250 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

1. Epicardial stenosis more than 50% by visual assessment.

Exclusion criteria

  1. STEMI.
  2. Hemodynamic instability.
  3. Rapid atrial fibrillation, flutter or arrhythmia (HR > 80 bpm).
  4. Insufficient CCTA image quality.
  5. Age <18 years.
  6. Chronic obstructive pulmonary disease.
  7. Contraindication to adenosine.
  8. NYHA class III or IV, or last known left ventricular ejection fraction <30%.
  9. Uncontrolled or recurrent ventricular tachycardia.
  10. History of recent stroke (≤90 days).
  11. Prior myocardial infarction.
  12. History of ischemic stroke (>90 days) with modified RANKIN score ≥ 2.
  13. History of any hemorrhagic stroke.
  14. Previous coronary artery bypass surgery.
  15. Active liver disease or hepatic dysfunction, defined as AST or ALT > 3 times the ULN.
  16. Severe renal dysfunction, defined as an eGFR <30 mL/min/1.73 m2.
  17. BMI >35 kg/m2.
  18. Nitrate intolerance
  19. Contra-indication to heart rate lowering drugs.
  20. Unable to provide written informed consent.

Trial contacts and locations

1

Loading...

Central trial contact

Sofie Pardaens, MSc, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems